Clinical Trial to Evaluate Magtein in Older Adults
Completed · Not applicable
Conditions studied: Mood, Anxiety
In brief
A randomized double blind placebo controlled trial to evaluate the effects of a specialized magnesium on mood states and sleep quality in older adults.
Key facts
- Study ID
- NCT02363634
- Run by
- Miami Research Associates
- People needed
- 50
- Starts
- 2012-08-01
- Expected to finish
- 2013-11-01
- Last updated by the study team
- 2015-02-16
Who can join
Age: 45 and older, up to 70. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Subject is aged 45 to 70 years
- Subject weighs between 50 and 100 kg.
- Subject complains of having changes in their memory and concentration abilities.
- Subject scores ≥ 12 and ≤ 28 on the Hamilton Anxiety Rating Scale (HAM-A)
- Subject scores > 5 on the Pittsburgh Sleep Quality Index (PSQI)
- Subject scores ≥ 24 on the Mini-Mental State Examination (MMSE) for the purpose of ruling out dementia and Alzheimer's disease
- Female subject is surgically sterile, post-menopausal or agrees to use an acceptable method of birth control as defined in section 2.6.
- Subject agrees to stop taking any vitamins, minerals, or dietary/herbal supplements he/she is currently taking at least 7 days prior to randomization and to not take any vitamins, minerals or dietary/herbal supplements other than the study product until after study completion.
- Subject is willing and able to comply with the protocol including:
- attending 4 visits, each of which are about 3 hours long;
- not drinking alcohol or exercising for the 24 hours prior to the visits;
- and not taking any vitamin, mineral, dietary or herbal supplements throughout the study.
- Subject is able to understand and sign the informed consent to participate in the study.
You may not qualify if…
- Subject has any of the following medical conditions:
- active heart disease
- uncontrolled high blood pressure (≥ 140/90 mmHg)
- renal or hepatic impairment/disease
- Type I or II diabetes
- bipolar disorder
- Parkinson's disease
- Alzheimer's disease
- dementia
- unstable thyroid disease
- diagnosed major affective disorder
- psychiatric disorder (hospitalized in the past year)
- immune disorder (such as HIV/AIDS)
- any medical condition deemed exclusionary by the Principal Investigator (PI)
- Subject has a history of cancer (except localized skin cancer without metastases or in situ cervical cancer) within 5 years prior to screening.
- Subject is currently taking calcium channel blockers, SSRI's or anxiolytics other than benzodiazepines as needed, with "as needed" defined as less than 5 times per month.
- Subject is currently taking any medications that are known to interact with magnesium (see section 2.5.2).
- Subject is currently taking antibiotics as the study product may reduce the absorption of antibiotics. A washout period of 2 weeks is allowed.
- Subject is on an unstable dose of medication (defined as fewer than 90 days at the same dose).
- Subject is currently taking any medication deemed exclusionary by PI.
- Subject has an allergy or sensitivity to any ingredient in the test product (see section 3.2.1).
- Subject exhibits evidence of hepatic or renal dysfunction as evidenced by ALT, AST, AP being ≥ 2 times the upper limit of normal or serum creatinine value ≥ 2.0 mg/dl or other clinically significant abnormal clinical laboratory value per PI discretion.
- Subject has a history of drug or alcohol abuse in the past 12 months.
- Subject has begun/stopped smoking ≤ 6 months ago OR has plans to begin/quit smoking.
- Subject is pregnant, lactating, or planning to become pregnant during the study period.
Where it is running
- Miami Research Associates — Miami, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.